Current Report Filing (8-k)
May 14 2019 - 07:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8‑K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported):
May 14,
2019
ENTASIS
THERAPEUTICS HOLDINGS INC.
(Exact name of registrant as
specified in its charter)
Delaware
|
001‑38670
|
82‑4592913
|
(state or other
jurisdiction of incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
35 Gatehouse
Drive
|
|
|
Waltham, Massachusetts
|
|
02451
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (781) 810‑0120
(Former
name or former address, if changed since last report.)
Check the appropriate
box below if the Form 8‑K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.
below):
|
¨
|
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
|
Soliciting material
pursuant to Rule 14a‑12 under the Exchange Act (17 CFR
240.14a‑12)
|
|
¨
|
|
Pre-commencement
communications pursuant to Rule 14d‑2(b) under the
Exchange Act (17 CFR 240.14d‑2(b))
|
|
¨
|
|
Pre-commencement
communications pursuant to Rule 13e‑4(c) under the
Exchange Act (17 CFR 240.13e‑4(c))
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in
as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b–2 of the Securities
Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth
company ☒
If an emerging growth
company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☒
Securities
registered pursuant to Section 12(b) of the Exchange
Act:
|
|
|
Title of each class:
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
Stock, $0.001 par value
|
ETTX
|
The
Nasdaq Stock Market, LLC
|
Item 2.02.
Results of Operations and Financial Condition.
On May 14, 2019, Entasis
Therapeutics Holdings Inc. (the “Company”) issued a press
release announcing its financial results for the quarter ended
March 31, 2019. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report on Form 8‑K and is
incorporated herein by reference.
The information provided in this
Form 8‑K, including Exhibit 99.1 hereto, shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any of the Company’s filings under
the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such
filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
,
|
|
|
|
ENTASIS THERAPEUTICS
HOLDINGS INC.
|
|
|
|
|
By:
|
/s/ Michael Gutch, Ph.D.
|
|
|
Michael Gutch, Ph.D.
|
|
|
Chief Financial Officer and Chief
Business Officer
|
Dated: May 14, 2019
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Dec 2020 to Jan 2021
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Jan 2020 to Jan 2021